Eltrombopag for the treatment of refractory connective tissue disease-related thrombocytopenia: a pilot study of 52 cases
Abstract Background The objective of this study was to investigate the therapeutic effectiveness and safety profile of Eltrombopag, a thrombopoietin receptor agonist, as prolonged therapy in refractory CTD-ITP patients. Methods We conducted a pilot observational study of Eltrombopag in CTD-ITP patie...
Saved in:
Main Authors: | Siying Deng, Bei Wang, Ziwei Hu, Shaozhe Cai, Lingli Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-024-03472-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01) -
Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature
by: Roberto Castelli, et al.
Published: (2025-02-01) -
Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)
by: M. V. Maevskaya, et al.
Published: (2024-08-01) -
Unveiling Thrombocytopenia Trends In Pediatric Epilepsy: The Valproate Connection
by: Kiran Nayab, et al.
Published: (2025-01-01) -
Decrease in platelet count in patients with AKI and its association with major adverse kidney events
by: Ramón Medina-González, et al.
Published: (2024-12-01)